Results 21 to 30 of about 4,708,479 (153)

Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) modeling aims to understand how a drug is absorbed, distributed, metabolized, excreted, and acts in a human or animal body.
Anthonia M. Onasanwo   +6 more
doaj   +2 more sources

Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients. [PDF]

open access: yesClin Pharmacol Ther
Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Jang YJ, Heo DG, Hong E.
europepmc   +2 more sources

Application in silico Modeling Simulation in Bioequivalence Studies: A Review

open access: yesJournal of Food and Pharmaceutical Sciences, 2023
Bioequivalence testing aims to ensure that the therapeutic performance of the drug is consistent and reproducible when it is administrated. Modeling and simulation in silico methods are currently performed to conduct virtual bioequivalence studies ...
Sekar Ayu Pawestri
doaj   +1 more source

Sex-Related Differences in Physiologically-Based Biopharmaceutics Modeling. [PDF]

open access: yesCPT Pharmacometrics Syst Pharmacol
Sex‐related differences in gastrointestinal tract physiology and their incorporation into three widely used PBPK platforms (PK‐Sim, GastroPlus, Simcyp) were evaluated. A ketoprofen PBPK model was developed and verified in males, then extrapolated to females using default and sex‐specific refined parameters, demonstrating that user‐defined adjustments ...
Chavarría-Rojas M   +4 more
europepmc   +2 more sources

Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development. [PDF]

open access: yesClin Transl Sci
Clinical and Translational Science, Volume 19, Issue 7, July 2026.
Dunn A, Lee S, Gobburu JVS.
europepmc   +2 more sources

Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK. [PDF]

open access: yesClin Pharmacol Ther
Although physiologically based pharmacokinetic (PBPK) modeling is increasingly being used to support oral drug formulation bridging, the acceptance by regulatory agencies is low. One of the primary concerns is the absence of clinical pharmacokinetic (PK) data from a non‐bioequivalent (non‐BE) batch during model validation.
Dong J   +6 more
europepmc   +2 more sources

Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling

open access: yesPharmaceutics, 2023
The most common method for establishing bioequivalence (BE) is to demonstrate similarity of concentration–time profiles in the systemic circulation, as a surrogate to the site of action.
Chunyan Han   +5 more
doaj   +1 more source

Virtual Bioequivalence Assessment of Long-Acting Injectable Suspensions Using PBPK Modeling: Part 2. Type I Error and Safe Space Analyses. [PDF]

open access: yesAAPS J
We present an analysis of statistical type I error and safe space calculations in virtual bioequivalence (VBE) assessments using a previously published physiologically-based pharmacokinetic (PBPK) model for 3-month long-acting paliperidone palmitate (PP) injectable suspensions.
Morris NM   +6 more
europepmc   +3 more sources

Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling

open access: yesFrontiers in Medicine, 2023
AimsSystemic pharmacokinetic (PK) studies can reflect the overall exposure of orally inhaled drug Products (OIDPs) in the blood after inhalation into the lung and can be used to evaluate the bioequivalence of test and reference products.
Jisheng Zhang   +7 more
doaj   +1 more source

From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs. [PDF]

open access: yesClin Pharmacol Ther
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Rowland Yeo K, van der Graaf PH.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy